Introduction
For two decades, running a multi-country clinical trial in Europe meant filing a separate application in every member state where the trial would take place, each with its own national authority, its own timelines, and its own quirks. The EU Clinical Trials Regulation (CTR, Regulation (EU) No 536/2014) and the Clinical Trials Information System (CTIS) that implements it were built to replace that patchwork with a single submission and a coordinated assessment. For regulatory affairs professionals working on European trials, this has changed not just the paperwork but the shape of the job itself.
This article explains what the CTR and CTIS actually changed, where the real regulatory affairs work now sits, and what it means for people building a career around European clinical development.
What the Clinical Trials Regulation Replaced
The CTR replaced the earlier Clinical Trials Directive, which had allowed each EU member state to implement clinical trial rules somewhat differently, producing real variation in submission requirements, timelines, and documentation expectations across the bloc. A sponsor running a trial in eight member states effectively had to manage eight separate regulatory relationships, each with its own clock, its own required translations, and its own opportunities for delay.
The CTR's central idea is a single application, submitted once through CTIS, that is assessed jointly by a reporting member state and the other concerned member states through a coordinated procedure with defined timelines. Member states still have a role, particularly on ethics and purely national matters, but the scientific and regulatory assessment of the core trial application is meant to proceed as one coordinated process rather than several parallel ones.
How CTIS Changes the Submission Process
CTIS is the single EU portal and database through which sponsors submit a clinical trial application, member states carry out their assessment, and the resulting trial information becomes publicly accessible once the required transparency rules apply. Rather than preparing separate national dossiers, a sponsor builds one submission package in CTIS that covers the full set of participating member states, with a reporting member state leading the scientific assessment of Part I of the application (covering, broadly, the trial's scientific and clinical aspects) and each member state separately assessing Part II (covering aspects like informed consent and local ethics requirements).
In practice, this means the regulatory affairs team's submission work is now concentrated into a single, more complex authoring and portal-management exercise rather than spread across multiple near-duplicate national filings. The system itself, workflow logic, document structure, and the public transparency layer, has become something regulatory professionals need to actively understand rather than treat as a simple filing cabinet.
The Single Assessment Model Across Member States
The coordinated assessment model under the CTR sets defined timelines for the reporting member state's initial evaluation, for the response to any requests for information, and for the other concerned member states to raise their own questions or objections. This is designed to produce a faster, more predictable overall timeline than the old system allowed, though it also means a request for information from any one member state has to be addressed in a way that satisfies the coordinated process, not negotiated separately on a country-by-country basis.
For regulatory teams, this has shifted some of the skill emphasis toward managing a single, higher-stakes response process well, since there is less room to resolve an issue quietly in one country while others proceed unaffected. A well-prepared, consistent initial submission matters more under this model than it did when each national dossier could be tailored and adjusted somewhat independently.
What This Means for Regulatory Affairs Teams Day to Day
Day to day, regulatory affairs professionals working on European trials now need working fluency in the CTIS portal itself: how to structure a submission, how to track the status of an application across the reporting and concerned member states, and how to manage the substantial administrative detail the system requires, including tracking which parts of a submission are public and which remain confidential.
Teams also have to plan differently. Because the coordinated assessment moves on a defined, somewhat less flexible clock, the quality and completeness of the initial dossier matters more than it used to, which has pushed more pre-submission internal review and quality control work earlier into the timeline. Amendments to ongoing trials also now flow through CTIS under harmonized rules, which has consolidated what used to be scattered national amendment processes into a single, more consistent procedure that regulatory teams have had to learn from scratch.
Transparency Requirements and Public Disclosure
One of the more significant practical changes under the CTR is the transparency model built into CTIS. Substantial portions of clinical trial applications, and later results, become publicly accessible through the system, with specific provisions allowing sponsors to request deferral of certain commercially sensitive information for a defined period. Regulatory affairs teams now have to think about public disclosure at the point of authoring a submission, not as an afterthought, deciding what needs deferral protection and making sure that request is properly justified and submitted alongside the application itself.
This has added a genuinely new dimension to regulatory writing for European trials: documents are being drafted with the knowledge that much of their content will become public, which changes how some sections are framed even when the underlying science does not change.
Where Companies Are Struggling
The transition to CTIS has not been without friction. Sponsors and regulatory teams have reported the portal's workflow and document management functionality as more complex to navigate than many expected, and the system's technical issues during its early years created real submission delays for some sponsors. The requirement that all ongoing trials eventually transition fully onto CTIS, rather than continuing under legacy national processes, has also created a one-time administrative burden for companies with large existing European trial portfolios that had to be migrated into the new system.
These growing pains have, if anything, increased the premium on regulatory professionals who already have direct, practical CTIS experience, since that experience is difficult to substitute with general EU regulatory knowledge alone.
New Skills and Roles This Is Creating
Some companies and CROs have created roles or responsibilities specifically focused on CTIS submission management, distinct from the broader clinical regulatory strategy role, reflecting how much specific, practical system knowledge the portal now requires. Skills in particular demand include direct CTIS submission and lifecycle management experience, familiarity with the coordinated assessment timelines and how to manage a request for information under them, and judgment about transparency and deferral requests.
- Hands-on experience submitting and managing applications through the CTIS portal
- Understanding of the coordinated assessment procedure and reporting member state dynamics
- Experience drafting clinical trial documentation with public disclosure requirements in mind
- Familiarity with transparency rules and the process for requesting deferral of sensitive information
- Ability to manage trial amendments under the CTR's harmonized procedures across multiple member states
What to Expect Next
As more of the historical backlog of trials fully transitions onto CTIS and both sponsors and member states gain more experience with the coordinated assessment model, the process is generally expected to become more predictable than it was in the regulation's early implementation years. Regulatory affairs professionals who built genuine CTIS expertise during this transition period are well positioned, since that practical system knowledge does not disappear as the process matures; if anything, it becomes a more durable differentiator as fewer teams are still learning the basics.
How This Compares to Working Under the Old National System
For regulatory professionals who worked under the previous Clinical Trials Directive, the shift is worth naming plainly. The old system rewarded people who understood the specific quirks of individual national authorities, where a particular country's ethics committee was slow, which member state tended to ask for extra chemistry detail, how translation requirements varied. That knowledge has not become worthless, member states still matter, but it has become less central than fluency with the coordinated procedure itself and the CTIS system that runs it.
This has created a real generational split in the field. Experienced regulatory professionals who built their careers on national-level relationships and country-specific knowledge have had to adapt to a more systematized, portal-driven process, while people newer to European clinical regulatory work are often building CTIS fluency as their first and primary frame of reference, without the old system to unlearn. Neither background is clearly better positioned; what matters most now is practical, current experience actually working inside the coordinated model, which is exactly why direct CTIS submission experience has become such a specific and valued line on a résumé.
Conclusion
The EU Clinical Trials Regulation and CTIS represent one of the more significant structural changes to clinical regulatory work in Europe in recent years, consolidating a fragmented national system into a single, coordinated process with real public transparency built in. For regulatory affairs professionals working on or hoping to work on European clinical trials, direct, practical familiarity with CTIS submission management is quickly becoming a standard expectation rather than a specialized extra.